ClinicalTrials.gg

Program

QL1206

Its studies are mostly in Osteoporosis · Neoplasm Metastasis · Osteoporosis, Postmenopausal, led by Qilu Pharmaceutical.

Furthest: phase 3, since Sep 25, 20195 company-led studies, 1 open or runningNext primary completion: Jan 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Qilu Pharmaceutical51 open or runningphase 3since Sep 25, 2019Aug 21, 2018Jan 2027phase 3 · NCT07062978

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 21, 2018First study: phase 1 study in Healthy PeopleFirst studyNCT03651947 · 168 enrolled · China
  2. Sep 25, 2019Phase 3 study in Osteoporosis, PostmenopausalNCT04128163 · 440 enrolled · China
  3. Dec 10, 2019Phase 1 study in Healthy PeopleNCT04213105 · 144 enrolled · China
  4. Sep 1, 2020Phase 3 study in Bone MetastasesNCT04550949 · 700 enrolled · China
  5. Jul 3, 2025Phase 3 study in Postmenopausal Women With Osteoporosis at High Risk of FractureNCT07062978 · 278 planned · China

Ahead

  1. Jan 2027Primary completion: phase 3 study in Postmenopausal Women With Osteoporosis at High Risk of FractureNCT07062978

TargetBeta

TNFSF11 →read by rule
“Tumor necrosis factor ligand superfamily member 11 inhibitor”ChEMBL 37, by rule

Other programs on TNFSF11

ProgramCompanyFurthest phaseStudies
DenosumabruleAmgenphase 479
SHR-2017Jiangsu HengRui Medicinephase 12

Studies

All 5 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07062978Postmenopausal Women With Osteoporosis at High Risk of Fracture · China3RecruitingJan 2027278
NCT04550949Bone Metastases · China3UNKNOWNMar 1, 2021700
NCT04213105Healthy People · China1UNKNOWNOct 31, 2020144
NCT04128163Osteoporosis, Postmenopausal · China3UNKNOWNAug 31, 2021440
NCT03651947Healthy People · China1CompletedNov 17, 2018168

How it is read

Names in the registry

  • “QL1206”, 5 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.